Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease - United States.
This report describes cases of septic shock, osteomyelitis, Clostridium difficile colitis, and paraspinal abscess resulting from treatments for chronic Lyme disease. Patients, clinicians, and public health practitioners should be aware that treatments for chronic Lyme disease can carry serious risks. PMID: 28617768 [PubMed - indexed for MEDLINE]
C. difficile is the most common organism to cause healthcare-associated infection (HAI) in the United States (Dubberke, Carling, Carrico, Donskey, Loo, McDonald, et al., 2014). C. diff infection (CDI) rates in Hematopoietic Stem Cell Transplant (HSCT) recipients are up to 9-fold higher than those in other inpatient units due to weakened immune systems, long hospitalizations and antibiotic treatments (Bruminhent, Wang, Hu, Wagner, Sunday, Hegarty, et al., 2014). The nursing team and Infection Prevention and Control (IPC) personnel on the HSCT unit noticed the cluster of HAI CDI.
Infection is a serious complication of hematopoietic stem cell transplantation (SCT). However, the optimum oral agent for antibacterial prophylaxis in SCT recipients remains uncertain. Different antibiotics might affect incidence of blood stream infections, resistance, Clostridium difficile, gut microbiome, GVHD and relapse. To explore this we started this first clinical trial of levofloxacin (Levo) versus ciprofloxacin (Cipro) at our center.Methods: This is a single center prospective randomized study.
The objective of this study is to determine the incidence of CDI during and after auto-HCT and to identify risk factors for the development of CDI including diagnosis.Methods: We performed a retrospective study to describe the epidemiology, timing, and risk factors for CDI among adult patients who received autologous HCTs at our center from January 2007 through December 2018.
Clostridium difficile infection (CDI) is a leading cause of hospital-acquired infection. Allogeneic hematopoietic stem cell transplant (aHSCT) recipients in the peri-transplant periods represent an especially vulnerable population due to chronic immunosuppression, prolonged hospital stays, and routine use of antibiotics (abx). Previous attempts to identify potential risk factors (RF) for CDI are inconsistent in the literature.
Clostridiodes difficile infections (CDI) are a significant cause of morbidity in the early transplant period, with reported incidences in hematopoietic cell transplant (HCT) recipients as high as 33%. Previously published data from our center found that 650 of 781 (83.2%) HCTs performed from 2010 to 2013 had a stool sample submitted for CD testing in the peritransplant setting. Testing identified 86 (13.2%) cases with CDI (12% in autologous and 17.5% in allogeneic HCT recipients), the majority being diagnosed within a week after transplantation.
Clostridium difficile infection (CDI) is a major source of morbidity for patients undergoing autologous and allogeneic hematopoietic stem cell transplantation (HSCT). CDI can complicate gastrointestinal mucositis, lead to mucosal barrier infections or sepsis, and compromise nutrition after HSCT. CDI may contribute to acute gastrointestinal graft-versus-host disease (GI aGVHD) and reduce overall survival in allogeneic HSCT patients. Use of enteral vancomycin as CDI prophylaxis may reduce morbidity and improve outcomes in HSCT recipients.
Sepsis continues to kill children around the world. The death of a child with sepsis in New York State resulted in a state-wide mandate for sepsis care in 2013 (JAMA 2018;320:358-67). This mandate was later found to be associated with lower risk of mortality from pediatric sepsis. Since then, other states have promulgated similar mandates.
Publication date: Available online 22 January 2020Source: American Journal of Infection ControlAuthor(s): Fibi Attia, Cynthia Whitener, Scott Mincemoyer, Justin Houck, Kathleen JulianUltraviolet (UV) light has destructive activity against pathogenic bacteria including Clostridioides difficile spores. Portable pulsed-xenon UV disinfecting devices were implemented for terminal room cleaning in 6 units of our academic hospital with high C. difficile infection (CDI) rates. CDI rates were measured in a 9-month period before and a 9-month period after device implementation. Despite documented administration of UV disinfection fo...
AbstractPurpose of ReviewEarly diagnosis of infections and immediate initiation of appropriate antimicrobials are crucial in the management of patients before and after organ transplantation. We reviewed the most recent literature and guidelines in this field and organized the current recommendations for healthcare professionals caring for critically ill organ transplant recipients.Recent FindingsThe incidence of multidrug-resistant organisms is increasing. Multidrug-resistant Gram-negative bacteria comprise about 14% of organisms. Vancomycin-resistant enterococci bloodstream infections are also on the rise, as 20.5% of no...
Publication date: Available online 23 January 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Richard R. Rustandi, Melissa HammAbstractCDTa, an actin ADP-ribosylation transferase, is a binary toxin produced by the bacterium Clostridium difficile which is commonly associated with the hypervirulent strain present in Clostridium difficile infections. The mutated form of CDTa, 4mCDTa, is one of the components in the tetravalent Clostridium difficile vaccine in which the residual toxicity of the ADP-ribosylation activity needs to be monitored for safety reasons. There are several ADP- ribosylation activi...